Suchergebnisse - "Dres Damgaard"

1

Relative efficiencies of peptidylarginine deiminase 2 and 4 in generating target sites for anti-citrullinated protein antibodies in fibrinogen, alpha-enolase and histone H3.

von: Dres Damgaard

2018, in: PLoS ONE

Wird geladen...
2

Reactive oxygen species inhibit catalytic activity of peptidylarginine deiminase

von: Dres Damgaard

2017, in: Journal of Enzyme Inhibition and Medicinal Chemistry

Wird geladen...
3

Calgizzarin (S100A11): a novel inflammatory mediator associated with disease activity of rheumatoid arthritis

von: Lucie Andres Cerezorbora sumova

2017, in: Arthritis research & therapy

Wird geladen...
4

Identification of potential autoantigens in anti-CCP-positive and anti-CCP-negative rheumatoid arthritis using citrulline-specific protein arrays

von: Thomas B. G. Poulsen

2021, in: Scientific Reports

Wird geladen...
5

Identification of Novel Native Autoantigens in Rheumatoid Arthritis

von: Thomas B. G. Poulsen

2020, in: Biomedicines

Wird geladen...
6

Peptidylarginine Deiminase 2 Gene Polymorphisms in Subjects with Periodontitis Predispose to Rheumatoid Arthritis

von: Laura Massarenti

2022, in: International Journal of Molecular Sciences

Wird geladen...
7

Calgizzarin (S100A11): a novel inflammatory mediator associated with disease activity of rheumatoid arthritis

von: Lucie Andrés Cerezo

2017, in: Arthritis Research & Therapy

Wird geladen...
8

PADI4 Polymorphisms Confer Risk of Anti-CCP-Positive Rheumatoid Arthritis in Synergy With HLA-DRB1*04 and Smoking

von: Laura Massarenti

2021, in: Frontiers in Immunology

Wird geladen...
9

S100A11 (calgizzarin) is released via NETosis in rheumatoid arthritis (RA) and stimulates IL-6 and TNF secretion by neutrophils

von: Adéla Navrátilová

2021, in: Scientific Reports

Wird geladen...
10

Applicability of Small-Molecule Inhibitors in the Study of Peptidyl Arginine Deiminase 2 (PAD2) and PAD4

von: María Teresa Martín Monreal

2021, in: Frontiers in Immunology

Wird geladen...

Nicht das Richtige dabei?

Schreiben Sie uns!